Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2025-08-25 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "瑞康医药集团股份有限公司2025 年半年度报告全文" which translates to "Realcan Pharmaceutical Group Co., Ltd. 2025 Semi-Annual Report Full Text." It explicitly states it is a half-year report for the period January 1, 2025 to June 30, 2025. The content includes detailed financial data, management discussion and analysis, business segment performance, and other comprehensive financial and operational information typical of an interim or quarterly report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is an announcement of a report or a certification letter. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-25 Chinese
2025年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "瑞康医药集团股份有限公司2025 年半年度财务报告" which translates to "Ruikang Pharmaceutical Group Co., Ltd. 2025 Semi-Annual Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, notes on accounting policies, and other comprehensive financial data for the half-year period ending June 30, 2025. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. The presence of actual financial data and analysis confirms it is a substantive financial report for a period shorter than a full fiscal year. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-25 Chinese
关于公司董事、董事会秘书及副总裁解除留置并变更为责令候查的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the change in status of a company director and senior management personnel (解除留置 and 责令候查 measures for a director, board secretary, and vice president). It does not contain financial data, audit information, or report content. It is specifically about management personnel status changes, which fits the Board/Management Information category (MANG). The document length is short and focused on personnel changes, not a report or financial disclosure.
2025-08-12 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase plan. It details the number of shares repurchased, prices, total amount spent, compliance with regulatory rules, and future intentions to continue the repurchase. It references prior announcements and regulatory guidelines but does not contain financial statements or comprehensive financial data. The document length is short (1538 characters) and focuses on the update of share buyback activity. Therefore, it fits the category of Transaction in Own Shares (POS), which covers reports of the company buying back its own shares.
2025-08-05 Chinese
关于公司董事、副总裁辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company director and vice president. It includes details about the resignation, its effect on the board, and the company's plans for replacement. There is no financial data, no mention of financial results, or any other report type. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2025-07-13 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase plan. It details the number of shares repurchased, prices, total amount spent, compliance with regulatory rules, and future intentions to continue the repurchase. It references prior announcements and regulatory guidelines but does not contain financial statements or detailed financial analysis. The document length is short (1538 characters) and focuses on the update of share buyback activity, which fits the definition of a Transaction in Own Shares (POS) filing rather than a full financial report or other categories.
2025-07-02 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.